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Abstract
Background: Renal cell carcinoma patients respond poorly to conventional chemotherapy, this
unresponsiveness may be attributable to multidrug resistance (MDR). The mechanisms of MDR in
renal cancer are not fully understood and the specific contribution of ABC transporter proteins
which have been implicated in the chemoresistance of various cancers has not been fully defined in
this disease.
Methods: In this retrospective study the expression of two of these transporter efflux pumps,
namely MDR-1 P-gp (ABCB1) and MRP-1 (ABCC1) were studied by immunohistochemistry in
archival material from 95 renal cell carcinoma patients.
Results: In the first study investigating MDR-1 P-gp and MRP-1 protein expression patterns in renal
cell carcinoma patients, high levels of expression of both efflux pumps are observed with 100% of
tumours studied showing MDR-1 P-gp and MRP-1 positivity.
Conclusion: Although these findings do not prove a causal role, the high frequency of tumours
expressing these efflux pumps suggests that they may be important contributors to the
chemoresistance of this tumour type.
Background
Kidney cancer accounts for approximately 2% of all adult
cancers. It is the 7th leading cause of cancer in the US with
an estimated incidence of approximately 51,000 new can-
cer cases per year in 2007 [1]. Renal cell carcinoma (RCC)
is the most common tumour arising from the cells in the
lining of tubules in the kidney [2]. At the time of diagno-
sis, 30% of patients will have metastatic or unresectable
disease, and the 2-year overall survival of this cohort is
<10% [3]. The incidence of kidney cancer is rising; it is 2
times more common in men than women. Risk factors
include obesity [4], smoking [5] and hypertension [6].
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RCC is a chemoresistant tumour usually exhibiting only a
marginal response. Radiotherapy and chemotherapy are
generally ineffective in the treatment of advanced renal
tumours [7,8]. The intrinsic occurrence of multidrug
resistance (MDR) modulates the resistance of tumours to
a wide variety of and structurally distinct chemotherapeu-
tic drugs through the expression of drug efflux pumps [9].
Two of the most widely studied efflux pumps, MDR-1 P-
gp/P-170, the gene product of MDR-1 (ABCB1) and MRP-
1 (ABCC1) which encodes a 190 kDa membrane protein
have both been demonstrated to pump a wide variety of
the most commonly used cancer drugs out of tumour
cells. Their over expression correlates broadly with drug
resistance in many different forms of cancer including
pancreatic cancer [10], lung cancer [11], breast cancer [12]
and glioma [13]. The relative contributions and causative
role, if any, of MDR associated protein efflux pumps in
renal carcinoma have not been fully elucidated.
Studies detailing the prevalence and contribution of
MDR-1 P-gp in RCC are conflicting. MDR-1 P-gp expres-
sion has been reported widely in untreated renal carcino-
mas [14,15]. It does appear that intrinsic drug resistance
exists in many renal RCC and it is associated, at least in
part, with increased expression of MDR-1 P-gp. However,
the exact prognostic significance of this expression
remains unclear with conflicting results described. Longer
progression free survival has been observed in patients
with none or very few MDR-1 P-gp positive tumour cells
compared to patients with a larger proportion of MDR-1
Pgp positive tumour cells [16,17]; however higher MDR-1
expression has been associated with a better outcome also
[18,19]. Expression of MDR-1 P-gp has been shown to
correlate with a well differentiated tumour phenotype in
renal carcinoma [18,20,21]. Higher MDR-1 gene expres-
sion has been observed in RCCs that have metastasised/
invaded through the renal capsule compared to early stage
non invasive tumours [20,22].
Studies addressing the contribution, if any, of the MRP-1
efflux pump and its gene product in this disease are lim-
ited. MRP-1, like MDR-1 P-gp is highly expressed in nor-
mal kidney. MRP-1 gene over expression has been
observed in renal carcinomas, this expression does not
appear to correlate with grade/clinical stage in this disease
[19,23]. To our knowledge, there have been no reported
studies looking at MRP-1 protein expression in RCC.
In this study, we evaluate the expression of MDR efflux
pumps, MDR-1 P-gp and MRP-1, using immunhisto-
chemical analysis, in 95 RCCs, to investigate the relative
contributions of these efflux pumps in this disease.
Methods
Patients
The patient group consisted of 95 consenting patients
diagnosed with primary renal cell carcinomas. All patients
were treated at St. Vincent's University Hospital (SVUH),
Dublin between 1999 and 2003. Approval to conduct this
study was granted by the SVUH Ethics Committee. Patho-
logical material was examined on each case by SK. Forma-
lin-fixed paraffin-embedded material was available for all
patients. Representative 4-μm sections of tissue blocks
were cut using a microtome, mounted onto poly-l-lysine
coated slides and dried overnight at 37°C. Slides were
stored at room temperature until required. Clinicopatho-
logical features, where available were compiled for rele-
vant patients.
Immunohistochemistry
Immunohistochemical studies were performed on forma-
lin fixed paraffin embedded renal carcinomas as described
previously [12]; using anti-MDR-1 P-gp (antibody MDR-
1, 6/1C; National Institute for Cellular Biotechnology
[24]: ascites diluted 1:40) and anti-MRP-1 (antibody
PA28(6), neat supernatant, National Institute for Cellular
Biotechnology [25]). Positive control tissues (normal kid-
ney and lung tissue) and negative control specimens in
which primary antibody was replaced by 1XTBS/0.05%
Tween 20 were included in all experiments.
Immunohistochemical scoring
MDR-1 P-gp and MRP-1 immunohistochemical staining
was evaluated semi-quantitatively, according to the per-
centage of cells showing specific immunoreactivity and
the intensity of this immunoreactivity. Scoring involved
evaluation of at least 5 fields of view per slide, by two
independent observers. In the case of both MDR-1 P-gp
and MRP-1, membrane and  cytoplasmic staining was
scored as positive or negative. A semi-quantitative meas-
urement was used in which overall positivity of the
tumour was assessed and a score of 1+ was given where up
to 25% of cells showed MDR-1 P-gp/MRP-1 positive stain-
ing; a score of 2+ was given where ≥ 25% but < 50% of
cells showed MDR-1 P-gp/MRP-1 positive staining; a score
of 3+, where ≥ 50% but <75% of cells showed positive
staining and a score of 4+, where ≥ 75% of cells showed
positive staining. For assessment of both MDR-1 P-gp and
MRP-1 protein, the intensity of immunoreactivity was
scored as 1 (weak), 2 (moderate), or 3 (strong) as outlined
in table 1.
Results
MDR-1/P-gp expression
The immunohistochemical analysis revealed that of the
95 cases, MDR-1 P-gp specific staining was observed
weakly positive in 22% (21/95), moderate staining was
observed in 40% (38/95) and strong staining in 38% (36/BMC Urology 2009, 9:6 http://www.biomedcentral.com/1471-2490/9/6
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95) of RCCs analysed. Figure 1(A) shows a representative
MDR-1 P-gp positive tumour where intense MDR-1 P-gp
positivity is observed (score of 4+3) and (B) MDR-1 P-gp
positive tumour with moderate staining intensity (score
of 2+2). Specific staining was localised to the cell mem-
brane and cytoplasm. The majority of tumours had
between 50–75% positive staining for MDR-1 P-gp, asso-
ciated with an intermediate (+2) intensity positive stain-
ing (3+2). 76% of tumours (72/95) showed MDR-1 P-gp
staining in 50% or more of tumour cells. As outlined in
Table 2, the distribution of MDR-1 P-gp expression was
analysed by percentage staining, age, gender, tumour size,
tumour grade and nodal status (if known). Of the 95
MDR-1 Pgp positive RCC, 6% (6/95) scored 1, 18% (17/
95) scored 2, 45% (43/95) scored 3 and 31% (29/95)
scored 4 percentage staining of MDR-1 Pg-p.
Table 1: Percentage and intensity grade of staining.
Percentage grade of staining Intensity grade of staining 
1 = 1<25% Level 1 = weak staining
2 = ≥25–50% Level 2 = moderate staining
3 = ≥50<75% Level 3 = strong staining
4 = ≥75<100%
Immunohistochemical analysis of MDR-1 P-gp and MRP-1 protein expression in RCC Figure 1
Immunohistochemical analysis of MDR-1 P-gp and MRP-1 protein expression in RCC. (A) RCC tumour showing 
positive MDR-1 P-gp staining with strong MDR-1 positivity observed, score (4+3) (scale bar = 100 μm) and (B) MDR-1 P-gp 
positive RCC with moderate positivity observed, score (2+2) (scale bar = 100 μm) (C) MRP-1 positive tumour showing intense 
MRP-1 positive staining, score (4+3) (scale bar = 100 μm) and (D) MRP-1 positive RCC with moderate positivity observed, 
score (2+2) (scale bar = 100 μm). (Original magnifications of all photomicrographs ×40).BMC Urology 2009, 9:6 http://www.biomedcentral.com/1471-2490/9/6
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Table 2: P-gp expression in renal cell carcinoma and association with age at diagnosis, tumour size, histological grade and nodal status 
(n = 95)
Number Strong (+3) Moderate (+2) Weak (+1)
Cases expressing P-gp 95
Percentage Staining
1+ (1<25%) 6 0 2 4
2+ (≥ 25–50%) 17 5 8 4
3+ (≥ 50<75%) 43 9 23 11
4+ (≥ 75%) 29 22 5 2
Age
< 60 41 20 13 8
> 60 54 16 25 13
Gender
Male 49 26 17 6
Female 46 10 21 15
Tumour size
< 7 cm 56 21 26 9
> 7 cm 39 15 12 12
Tumour grade (7 unknown)
Grade 1 16 5 8 3
Grade 2 35 16 15 4
Grade 3 37 13 13 11
Nodal status (56 unknown)
Positive 31 10 15 6
Negative 8 2 4 2
Table 3: MRP-1 expression in renal cell carcinoma and association with age at diagnosis, tumour size, histological grade and nodal 
status (n = 95)
Number Strong (+3) Moderate (+2) Weak (+1)
Cases expressing MRP-1 95
Percentage Staining
1+ (1< 25%) 7 0 2 5
2+ (≥ 25–50%) 30 2 16 12
3+ (≥ 50<75%) 38 13 23 2
4+ (≥ 75%) 20 13 6 1
Age
< 60 41 14 19 8
> 60 54 14 28 12
Gender
Male 49 15 25 9
Female 46 13 22 11
Tumour size
< 7 cm 56 14 29 13
> 7 cm 39 14 17 7
Tumour grade (7 unknown)
Grade 1 16 5 7 4
Grade 2 35 8 19 8
Grade 3 37 14 17 6
Nodal status (56 unknown)
Positive 31 8 17 6
Negative 8 2 3 3BMC Urology 2009, 9:6 http://www.biomedcentral.com/1471-2490/9/6
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MRP-1 expression
All 95 RCCs showed MRP-1 protein expression; MRP-1
specific staining was observed weakly positive in 21%
(20/95), moderate staining was observed in 49% (47/95)
and strong staining observed in 29% (27/95) of RCC ana-
lysed. Figure 1(C) illustrates an MRP-1 strongly positive
(score of 4+3) tumour and (D) an MRP-1 positive tumour
showing less intense MRP-1 staining (score of 2+2). Table
3 shows a breakdown of the distribution of MRP-1 posi-
tive tumours. Of the cases expressing MRP-1, 7% (7/95)
scored 1, 32% (30/113) scored 2, 40% (38/95) scored 3
and 21% (20/95) scored 4. 61% of tumours (58/95)
showed MRP-1 staining in 50% or more of tumour cells.
The highest percentage staining and intensity of MRP-1
expression was observed in male patients over the age of
60 with grade 2 tumours of < 7 cm in size and with posi-
tive nodal status.
Correlation between MDR-1 P-gp and MRP-1
All tumours studied expressed both MDR-1 P-gp and
MRP-1; intensity levels of these transporters did not vary
to any great degree, however a higher proportion (76%) of
MDR-1 positive tumours exhibited positive staining in
50% or more of tumour cells compared to MRP-1 staining
patterns where 61% of MRP-1 positive tumours exhibited
staining in 50% or more of tumour cells.
Discussion
Chemotherapy is the standard treatment for most solid
tumours; however, RCC is generally resistant to chemo-
therapy. The reason for the resistance of kidney cancer
cells to chemotherapy is not completely understood. The
specific role and relative contributions of ABC transporter
pumps in clinical resistance in RCC have not been fully
determined; results from previous studies are conflicting.
The MDR1 gene and its gene product, P-gp are ubiqui-
tously expressed in mesangial, proximal tubule, thick
loop of Henle, and collecting duct cells of the kidney [26].
As P-gp plays a functional role in the clearance of xenobi-
otics from the mesangial and proximal tubule cells of the
kidney, this may contribute to the inherent multidrug
resistance phenotype of RCC. MDR-1 gene overexpression
or protein have been identified in the majority of RCC
samples studied [14-17,19,21].
In this reterospective study we have shown that renal can-
cer cells produce an overabundance of this drug efflux
pump, with 100% of RCCs studied exhibiting MDR-1 P-
gp positivity. 76% of these tumours exhibited MDR-1 P-
gp staining in 50% or more of tumour cells. As renal tissue
inherently expresses high levels of this transporter; results
presented here are not unexpected. Using a similar scoring
system as that used here, Mignogna et al., [16] observed
MDR-1 P-gp expression in 100% (30/30) of RCC. Other
immunohistochemical studies on smaller patient cohorts
report 61.5% (8/13) and 47.6% (10/21) of RCC showing
MDR-1 P-gp positivity [14,15]; studies investigating
MDR-1 gene expression in RCC report varying levels of
gene expression, in general slightly less that the MDR-1 P-
gp protein expression observed here [19-23]. It is well rec-
ognised that protein levels do not necessarily correlate
with mRNA levels, furthermore these differences between
the various studies may in part result from the different
techniques employed and different cohorts of patients
and scoring criteria used. The high levels of MDR-1 P-gp
expression observed here do suggest that this transporter
protein is contributing, at least in part, to the chemoresist-
ance of RCCs studied here.
Mignogna et al., [16] suggested a role for MDR-1 P-gp as a
possible adverse prognostic factor of chemoresistance and
aggressive behaviour in renal carcinoma, their study
showed an association between high MDR-1 P-gp expres-
sion (MDR-1 positivity in 40% or more of tumour cells)
and poor survival as confirmed by Cox multivariate anal-
ysis. In agreement with this study, Duensing et al., [17]
suggested a potential role for P-gp as a biologic parameter
predictive of tumour progression in renal cell carcinoma
patients, as longer disease-free survival was observed in
patients with <1% MDR-1 postivity. However, Hofmockel
et al., [18] correlated lower MDR-1 expression with poorer
prognosis. Due to the lack of data regarding patient out-
come; any possible prognostic significance of the expres-
sion of these efflux pumps observed could not be
addressed in this study.
Expression of this efflux pump does not appear to be asso-
ciated with the histological tumour grade of RCC in this
patient cohort. Unexpectedly lower MDR-1 levels have
been shown to be associated with poorly differentiated
RCC [18,20-22]. However, in agreement with our obser-
vations Mignogna et al., showed MDR-1 protein expres-
sion as having prognostic significance independent of any
association with tumour grade [16].
We have also shown high levels of MRP-1 protein expres-
sion in RCC; all tumours investigated showed MRP-1 pro-
tein expression with 61% of tumours exhibiting MRP-1
positivity in at least 50% of tumour cells. As in the case of
MDR-1 Pgp, this efflux pump is also expressed at high lev-
els in the normal kidney; so such an observed high level
of expression again is not unexpected. This is the first
report to our knowledge of MRP-1 protein expression
being investigated in RCC patients, previous work has
focused on gene expression studies. Again, this observed
high level of MRP-1 protein expression suggests that this
efflux pump also may be playing a contributing role in the
chemoresistance of these renal carcinomas.BMC Urology 2009, 9:6 http://www.biomedcentral.com/1471-2490/9/6
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There was no apparent correlation between expression of
either of the MDR proteins studied here with other clin-
icopathological features (gender, tumour size and nodal
status). It was unfeasible to carry out detailed statistical
analysis due to limitations and inadequate data. Histolog-
ical grade, pathological stage and tumour size have been
demonstrated using multivariate analysis to be significant
prognostic indicators regarding RCC patient outcome
[27]. Recently described molecular and genetic markers
may also provide diagnostic and prognostic value in RCC
[28].
It is likely that chemoresistance in RCC is multifactorial,
other factors implicated as being involved in the complex
chemoresistance mechanisms of RCC include Clusterin
[29]; there also is some evidence that lung resistance pro-
tein (LRP/MVP) may contribute to inherently resistant
renal carcinoma [30,31].
The inherent resistance of RCC to conventional treatment
has lead to the use of immunotherapies such as alpha-
interferon and interleukin-2 (IL-2). However, response
does not translate to long-term benefit and does not pro-
long overall survival in many cases [32-34]. Newer "tar-
geted-therapies" such as sunitinib [34,35] are emerging
for the treatment of patients resistant/intolerant to current
treatment modalities or as an alternative to cytokine
immunotherapy. Identification of new tumour associated
antigens may hopefully provide the basis of new thera-
peutic strategies and lead to an improved outcome for this
aggressive and chemoresistant disease.
Conclusion
Both MDR-1 P-gp and MRP-1 were expressed in 100% of
the 95 specimens analysed. These high levels of expres-
sion suggest that both of these efflux pumps may be
important contributors to the MDR phenotype in RCC.
The incidence of MRP-1 positive tumours observed here
warrants further study in order to confirm a possible con-
tribution to chemoresistance in renal carcinoma. Due to
the lack of data on the direct outcome of patients in this
study, the prognostic significance of observed MDR pro-
tein expression was outside the scope of this investigation.
Extensive studies with complete follow-up detailing
expression of MDR-1 P-gp and MRP-1 together with fur-
ther MDR associated markers (including LRP and MRP
family members) and associated proteins may help to
fully elucidate the specific contributions of these efflux
pumps to the chemoresistance of RCC and furthermore
address any possible prognostic and/or predictive role.
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